Keywords
How to Cite
Abstract
Primary immune thrombocytopenia (ITP) is defined as an autoimmune disorder characterized by a decreased platelet count to less than 100,000/μl, without other associated cytopenia. The clinical presentation may vary, from an asymptomatic patient to mild or severe bleeding associated with vital organs injury. The initial challenge of primary ITP is diagnosis by exclusion, as it requires the ruling out of multiple causes that may lead to a decrease in platelet count. The first-line treatment consists mainly on the use of corticosteroids, with a 60% effectiveness. Concomitant use of gammaglobulin is reserved for patients with bleeding complications, or those who do not respond to corticosteroids and require a second-line treatment. In the present article, 44 ITP cases were evaluated at the Sanatorio Güemes, in Buenos Aires, all of whom underwent first-line treatment with corticosteroids, focusing in our experience with the use of trombopoietin receptor agonists as second line treatment.
References
2. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113:2386.
3. Michele P, Lambert, Gernssheimer T. Clinical updates in adult immune thrombocytopenia. Blood. 2017; 129:2829-2835.
4. Stasi R, Newland AC. ITP: a historical perspective. British Journal of Haematology. 2011 153(4), 437-450.
5. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120:960.
6. George JN. Sequence of treatments for adults with primary immune thrombocytopenia. American Journal of Hematology. 2012; 87(S1), S12-S15.
7. Neunert C, Lim W, Crowther M et al. The American Society of Hematology evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117:4190.
8. Raymond S et al. Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study. Blood. 2017; 130:3628.
9. Cheng G, Saleh MN, Marcher C et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet. 2011; 377(9763), 393-402.
10. Raslova H, Vainchenker W & Plo I. Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica. 2016; 101(12), 1443-1445.
11. Wang B, Nichol J, Sullivan T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004 Dec;76(6):628-38.
12. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2):168.
13. Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. British Journal of Haematology. 2018; 181(2), 183-195.
14. Ghanima W, Geyer JT, Lee CS et al. Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up. Haematologica. 2014 May;99(5):937-44.
15. Ruggeri M, Tosetto A, Palandri F et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. Journal of Thrombosis and Haemostasis. 2014; 12(8), 1266-1273.
16. Rapetti M, Donato H, Fassi D y col. Trombocitopenia Inmune. Guías de diagnóstico y tratamiento, Sociedad Argentina de Hematología. 2017; 213-227.
17. Donato, H, Fassi D y col, Trombocitopenia Inmune. Guías de diagnóstico y tratamiento, Sociedad Argentina de Hematología. 2019; 219-235.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar